Getinge AB stock (SE0000202624): orders and earnings keep medtech group in focus

Getinge AB remains in focus after recent first-quarter 2025 results and new orders in its life science and acute care segments. The medtech group is watched by international and US investors for its surgical, ICU and sterilization equipment portfolio.

Getinge AB has stayed on the radar of international investors following the publication of its first-quarter 2025 results in April and continued order intake across key product areas such as acute care therapy and life science. The Swedish medtech group reported higher organic order growth and stable profitability in the period, according to a quarterly report released on April 23, 2025, and related materials on its investor website, as noted by Getinge investor information as of 04/23/2025. In parallel, the company has highlighted demand for equipment used in operating rooms, intensive care units and sterile reprocessing, which are areas of structural need in many healthcare systems, including the United States.

Beyond earnings, Getinge has continued to communicate on contracts and product initiatives that underline its role in hospital infrastructure and life science production. These include installations of sterilizers, washers and other infection-control solutions for healthcare and biopharma customers, according to recent updates on its corporate website and news feed, as referenced in Getinge press releases as of 03/20/2025. For US-focused investors, the stock offers indirect exposure to capital spending in hospitals and research facilities, a theme that tends to move with public and private healthcare budgets over time.

As of: 05/18/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Getinge B
• Sector/industry: Medical technology and life science equipment
• Headquarters/country: Gothenburg, Sweden
• Core markets: Hospitals, intensive care units, operating rooms and life science production facilities worldwide
• Key revenue drivers: Acute care therapy capital equipment and consumables, surgical workflows, sterile reprocessing and life science systems
• Home exchange/listing venue: Nasdaq Stockholm (GETI B)
• Trading currency: Swedish krona (SEK)

Getinge AB: core business model

Getinge AB operates as a global supplier of medical technology and related services, with a focus on equipment that supports clinical workflows in hospitals and advanced production environments in life sciences. The company’s portfolio is typically organized around areas such as acute care therapy, surgical workflows and life science solutions, as outlined in its corporate profile on the group website, according to Getinge corporate information as of 03/31/2025. This structure reflects the different types of customers served, ranging from hospital procurement teams to pharmaceutical manufacturers.

In acute care therapy, Getinge provides devices such as ventilators, anesthesia machines and heart-lung support systems that are used in intensive care units and operating rooms. These products are often mission-critical in the treatment of respiratory failure, surgical procedures and cardiovascular interventions, and are subject to strict regulatory standards. The business model combines upfront capital sales of equipment with recurring revenue from consumables, accessories and service contracts over the lifetime of the installed base.

The surgical workflows segment encompasses solutions that help hospitals plan, equip and manage operating rooms efficiently and with a focus on infection prevention. This can include operating tables, lights, ceiling supply units and integrated digital platforms that connect devices and data. The goal is to support hospitals in achieving higher utilization of operating theaters while maintaining quality and safety standards, as indicated in product descriptions on the group’s website, based on Getinge solutions overview as of 02/28/2025.

Getinge also addresses life science customers with equipment for biopharmaceutical production and laboratory applications. This includes bioreactors, sterilizers and washers designed for use in cleanroom environments and compliance with stringent validation requirements. For these customers, reliability, documentation and lifecycle support are central parts of the value proposition, since equipment downtime can disrupt production schedules and regulatory compliance. The company markets these offerings globally, including in North America, Europe and Asia, aiming to serve both large multinational drug makers and smaller contract manufacturers.

The group’s business model emphasizes long-term relationships with hospitals and life science clients through service, training and technical support. Service contracts, spare parts and software updates are important components of recurring revenue and can help smooth earnings over the cycle. This approach is visible in the company’s communication about its installed base and service capabilities in different regions, as highlighted in its annual reporting and investor presentations, according to Getinge annual reporting as of 03/20/2025.

Main revenue and product drivers for Getinge AB

Revenue at Getinge is driven by a mix of capital equipment sales and recurring income from consumables, accessories and service. In acute care therapy, ventilators and related devices gained visibility during the COVID-19 pandemic, but demand has continued to be influenced by broader ICU capacity planning and replacement cycles. This segment also includes devices for extracorporeal life support and cardiovascular procedures, where clinical outcomes and product reliability are key differentiators, as underlined in technical documentation and marketing material referenced via Getinge intensive care solutions as of 01/31/2025.

Surgical workflows contribute significantly to revenue through operating room equipment, particularly in markets where hospitals are expanding or upgrading their infrastructure. In developed healthcare systems, including parts of the United States, Europe and Japan, sales can be driven by modernization programs and replacement of legacy equipment. In emerging markets, new hospital construction and rising healthcare spending create additional demand. These project-based sales tend to be cyclical, but they also expand the installed base from which service and consumables revenue can be generated.

Life science solutions form another important revenue pillar, as the company supplies equipment to biopharmaceutical producers and research facilities. Demand in this area is linked to investment cycles in bioprocessing capacity, vaccine production and advanced therapies, among other segments. The pandemic years highlighted the importance of flexible and scalable bioprocessing infrastructure, and Getinge’s solutions aim to address such needs. Long-term supply agreements and framework contracts can provide visibility on volumes, though the timing of orders may still be uneven across quarters, according to commentary in management presentations summarized in Getinge investor calendar documents as of 04/15/2025.

From a regional perspective, Europe and North America are key markets, with the United States playing a significant role due to the size and sophistication of its hospital and life science industries. Getinge sells into the US market with products that must comply with FDA and other regulatory requirements, and competition includes large multinational medtech groups as well as niche specialists. Performance in the US can influence investor sentiment because it is often seen as a benchmark for global competitiveness in medical technology.

The company’s reported financials typically highlight orders, net sales and adjusted EBITA margins by segment, providing insight into which areas are driving growth and profitability in a given period. For the first quarter of 2025, management pointed to improved order intake in several product categories and disciplined cost control, according to the interim report released on April 23, 2025 and associated comments, as presented in Getinge quarterly report information as of 04/23/2025. Such metrics are closely watched by investors to assess whether recent demand trends are likely to support revenue and earnings over the coming quarters.

Why Getinge AB matters for US investors

For investors based in the United States, Getinge AB offers exposure to global trends in hospital infrastructure, intensive care and biopharmaceutical manufacturing without being tied solely to the US domestic medtech universe. The company’s equipment is installed in hospitals and research facilities across North America, meaning that its performance is influenced by purchasing decisions of US healthcare providers and life science companies. This can make the stock relevant to those following capital spending cycles in healthcare and drug development, alongside US-listed peers.

Getinge’s listing on Nasdaq Stockholm means that US investors typically access the shares via international brokerage platforms or through funds and ETFs with Nordic or European healthcare exposure. Currency is another consideration, as the stock trades in Swedish krona, so returns for dollar-based investors are affected by SEK/USD exchange rate movements over time. Some portfolio managers view such international holdings as a way to diversify away from purely US-dollar assets while retaining exposure to global healthcare themes.

Regulatory and reimbursement developments in the US market, such as hospital funding mechanisms, Medicare and Medicaid policies, and private insurer behavior, can influence demand for capital equipment and services. While Getinge is not a US-headquartered company, its products must remain competitive on value and clinical outcomes to secure contracts in this environment. As a result, factors like technology innovation, service quality and the ability to support hospitals in meeting quality and safety standards are closely linked to the group’s prospects in North America.

Conclusion

Getinge AB remains an established player in medical technology and life science equipment, with a business model built around acute care therapy, surgical workflows and specialized life science solutions. Recent quarterly results and ongoing order activity illustrate how capital projects, service contracts and consumables can shape its revenue and earnings profile over time. For US-focused investors, the stock provides exposure to hospital and biopharma investment trends in multiple regions, while also introducing factors such as Swedish currency and European regulatory dynamics. As with any medtech investment, future performance will depend on demand for critical care and surgical equipment, competitive positioning and the company’s ability to execute on its strategy across key markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.